Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia

NCTID	NCT06451770 (View at clinicaltrials.gov)
Description	VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia. VERVE-201 uses base-editing technology designed to inactivate the expression of the ANGPTL3 gene in the liver and lower circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides. This study is designed to determine the safety and pharmacodynamic profile of VERVE-201 in this patient population. (Show More)
Development Status	Active
Indication	Hypercholesterolemia
Disease Ontology Term	DOID:13810
Compound Name	VERVE-201
Sponsor	Verve Therapeutics, Inc.
Funder Type	Industry
Recruitment Status	Recruiting (Click here for study contact information)
Enrollment Count	36 (ESTIMATED)
Results Posted	Not Available

Eligible Age	18 Years - 70 Years
Standard Ages	Adult, Older adult
Sexes Eligible for Study	ALL
Eligibility Criteria	Inclusion Criteria: * Refractory hypercholesterolemia * Refractory hypertriglyceridemia Exclusion Criteria: * Active or history of chronic liver disease * Current treatment with monoclonal antibody targeting ANGPTL3 or prior treatment within specified timeframe * Clinically significant or abnormal laboratory values as defined by the protocol View Inclusion and Exclusion Criteria at ClinicalTrials.gov

No.of Trial Sites	10
Locations	Canada,South Africa,United Kingdom,Australia

Has US IND	True
FDA Designations
Recent Updates	Verve was acquired by Lilly in July 2025